Clinical experience with the freedom SOLO stentless aortic valve in 277 consecutive patients.

Thalmann, Markus; Kaiblinger, Josef; Krausler, Richard; Pisarik, Harald; Veit, Franz; Taheri, Niuscha; Kornigg, Karin; Dinges, Christian; Grabenwöger, Martin; Stanger, Olaf (2014). Clinical experience with the freedom SOLO stentless aortic valve in 277 consecutive patients. The Annals of Thoracic Surgery, 98(4), pp. 1301-1307. Elsevier 10.1016/j.athoracsur.2014.05.089

[img] Text
1-s2.0-S0003497514012922-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (258kB) | Request a copy

BACKGROUND The Sorin Freedom SOLO (FS) bovine pericardial stentless valve prosthesis is designed for supraannular, subcoronary implantation. We report our experience and results with 277 consecutively implanted FS bioprostheses. METHODS 277 patients (mean age, 74.2 ± 7.3 years; 139 (50.2%) female) underwent aortic valve replacement (AVR) with the FS stentless bioprosthesis. The hemodynamic performance was investigated with transthoracic echocardiography at discharge, 6 months later, and yearly thereafter. Follow-up was 100% complete, with an average observation time of 2.6 ± 1.7 years and a total of 697.3 patient-years. RESULTS The overall 30-day mortality was 4.3%. The mortalities for isolated AVR and combined procedures were 1.9% and 7.3%, respectively. No causes of death were valve-related. Preoperative peak (74.2 ± 23.0 mm Hg) and mean (48.6 ± 16.3 mm Hg) gradients decreased to 15.6 ± 5.4 mm Hg and 8.8 ± 3.0 mm Hg postoperatively and remained unchanged for as long as 5 years. The postoperative mean effective orifice area (EOA) for valve sizes 19, 21, 23, 25, and 27 were 1.49 ± 0.32 cm(2), 1.67 ± 0.40 cm(2), 1.92 ± 0.38 cm(2), 2.01 ± 0.42 cm(2), and 2.13 ± 0.36 cm(2), respectively. Severe prosthesis-patient mismach (PPM) was completely absent, and moderate PPM occurred in 17 patients (6.1%). In isolated AVR, 0.8% of patients with preoperative sinus rhythm required a permanent pacemaker before hospital discharge. There was 100% freedom from structural valve deterioration, 99.6 % freedom from endocarditis and reoperation, and 97.3% freedom from thromboembolism at 5 years. CONCLUSIONS The FS stentless aortic valve is safe to implant, and it shows excellent hemodynamic performance and early and midterm results. Owing to the favorable EOA, the valve appears particularly attractive for patients at risk for PPM.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiovascular Surgery

UniBE Contributor:

Stanger, Olaf


600 Technology > 610 Medicine & health








Sara Baumberger

Date Deposited:

17 Feb 2015 13:25

Last Modified:

27 Oct 2015 11:28

Publisher DOI:


PubMed ID:





Actions (login required)

Edit item Edit item
Provide Feedback